United Kingdom has expanded post-market surveillance obligations for infusion pumps, pacemakers, and defibrillators through updated regulations, and extended requirements to include catheters and medical infusion devices under new mandates.
UK Tightens Safety Rules for High-Risk Devices
Manufacturers of pumps and heart devices must report performance data.
What changed
Surveillance expanded for infusion pumps, pacemakers, and defibrillators.
Requirements extended to catheters and medical infusion devices.
Mandatory reporting and data collection obligations established.
HS code alignment required for compliance tracking.
Who it affects
Manufacturers must maintain and report on device performance and safety data.
Key dates
Regulation Analysis: Expanded Post-Market Surveillance (PMS) Obligations for Medical Devices in the UK
The UK has strengthened and expanded post-market surveillance (PMS) requirements for medical devices, including infusion pumps, pacemakers, defibrillators, catheters, and medical infusion devices, through two key legislative updates: The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2023 and The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024. These amendments introduce clearer, risk-proportionate obligations to improve safety monitoring, incident reporting, and regulatory oversight.
Key Changes and Requirements
1. Expanded Scope of Devices
The new regulations broaden the range of devices subject to enhanced PMS requirements. This includes:
- Active implantable medical devices (e.g., pacemakers, defibrillators)1.
- General medical devices (e.g., infusion pumps, catheters, medical infusion devices)1.
- CE-marked devices placed on the Great Britain (GB) market1.
2. Enhanced PMS System Requirements
Manufacturers must now implement detailed PMS systems that include:
- Methods for collecting PMS data to ensure consistency and harmonisation across manufacturers1.
- Periodic reviews of PMS data, particularly for implantable devices, to detect safety trends or signals earlier1.
- Improved coordination between manufacturers, UK Approved Bodies, and the Medicines and Healthcare products Regulatory Agency (MHRA) to support regulatory oversight1.
3. Stricter Incident Reporting Obligations
- Serious incident reporting has been enhanced to enable faster detection of safety issues1.
- Manufacturers must now report incidents sooner and provide greater traceability of trends to the MHRA2, 1.
4. Clarity and Risk Proportionality
The amendments aim to:
- Replace high-level PMS provisions in the Medical Devices Regulations 2002 with clearer, risk-proportionate requirements1.
- Reduce inconsistencies in how manufacturers conduct PMS activities1.
- Improve the quality of adverse incident data reported to the MHRA1.
Regulatory Timeline and Enforcement
| Regulation | Key Requirement | Deadline/Threshold | Authority |
|---|---|---|---|
| The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2023 | Introduces risk-proportionate PMS requirements, including data collection methods and periodic reviews1. | Entry into force: June 20241 | MHRA1 |
| The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 | Strengthens PMS obligations, prioritises patient safety, and enhances traceability of incidents2. | Entry into force: June 20252 | MHRA2 |
Summary Answer
The UK has expanded post-market surveillance obligations for infusion pumps, pacemakers, defibrillators, catheters, and medical infusion devices through The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2023 and 2024. Key changes include:
- Broader device scope, including CE-marked devices1.
- Detailed PMS system requirements, such as data collection methods and periodic reviews1.
- Enhanced serious incident reporting to detect safety issues sooner2, 1.
- Improved coordination between manufacturers, UK Approved Bodies, and the MHRA1.
- Risk-proportionate obligations to replace high-level provisions in the Medical Devices Regulations 20021.
The 2023 Regulations entered into force in June 2024, while the 2024 Regulations will take effect in June 20252, 1. These measures aim to improve patient safety, regulatory oversight, and incident traceability in the GB market.
Sources
- ↩ The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2023 _notification https://docs.wto.org/imrd/directdoc.asp?DDFDocuments/T/G/TBTN23/GBR64.DOCX
- ↩ The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 _notification https://docs.wto.org/imrd/directdoc.asp?DDFDocuments/T/G/TBTN23/GBR64A1.DOCX